This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DMTK DermTech (DMTK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About DermTech Stock (NASDAQ:DMTK) 30 days 90 days 365 days Advanced Chart Get DermTech alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.05▼$0.4252-Week Range N/AVolume3.66 million shsAverage Volume1.07 million shsMarket Capitalization$3.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California. Read More Receive DMTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter. Email Address DMTK Stock News HeadlinesDERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 10, 2025 | globenewswire.comNorth American Morning Briefing: TSMC Earnings -2-October 18, 2024 | morningstar.comMAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st. | Paradigm Press (Ad)DermTech, Inc. (DMTKQ)September 27, 2024 | finance.yahoo.comVictory RS Small Cap Growth ASeptember 8, 2024 | morningstar.comMWhy Is DermTech (DMTK) Stock Down 26% Today?June 24, 2024 | investorplace.comDermTech Files for Voluntary Chapter 11 ProtectionJune 18, 2024 | businesswire.comDMTK Stock Earnings: DermTech Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | investorplace.comSee More Headlines DMTK Stock Analysis - Frequently Asked Questions How were DermTech's earnings last quarter? DermTech, Inc. (NASDAQ:DMTK) posted its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.65) by $0.03. The business had revenue of $3.03 million for the quarter, compared to analyst estimates of $3.40 million. DermTech had a negative trailing twelve-month return on equity of 138.79% and a negative net margin of 572.19%. What other stocks do shareholders of DermTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that DermTech investors own include CrowdStrike (CRWD), NVIDIA (NVDA), Digital Turbine (APPS), Datadog (DDOG) and Cloudflare (NET). Company Calendar Last Earnings11/09/2021Today7/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:DMTK CIK1651944 Webwww.dermtech.com Phone(858) 450-4222FaxN/AEmployees260Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$100.89 million Net Margins-572.19% Pretax Margin-572.19% Return on Equity-138.79% Return on Assets-68.96% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.46 Sales & Book Value Annual Sales$15.66 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / BookN/AMiscellaneous Outstanding Shares34,963,000Free Float33,180,000Market Cap$3.29 million OptionableOptionable Beta2.48 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:DMTK) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DermTech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DermTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.